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Dose-escalation study was performed to evaluate the maximum tolerated dose, recommended dose and toxicity proﬁle of
weekly irinotecan with daily carboplatin and concurrent thoracic radiotherapy in patients with locally advanced non-small-cell
lung cancer. Thirty-one previously untreated patients with unresectable stage III non-small-cell lung cancer were enrolled in this
study. Patients received weekly irinotecan plus carboplatin (20 mg m
72 daily for 5 days a week) for 4 weeks and thoracic
radiotherapy (60 Gy in 30 fractions). The irinotecan dose was escalated from 30 mg m
72 in increments of 10 mg m
72. Four
irinotecan dose levels were given and 30 patients were assessable. Their median age was 62 years (range: 52–72 years), 28 had
a performance status of 0–1 and two had a performance status of 2, 12 had stage IIIA disease and 18 had IIIB disease. There
were 19 squamous cell carcinomas, 10 adenocarcinomas, and one large cell carcinoma. The dose-limiting toxicities were
pneumonitis, esophagitis, thrombocytopenia and neutropenia. The maximum tolerated dose of irinotecan was 60 mg m
72, with
two patients developing grade 4 pulmonary toxicity and one patient died of pneumonitis (grade 5). The recommended dose of
irinotecan was 50 mg m
72. Other grade 3 or 4 toxicities were nausea and vomiting. Three patients achieved complete
remission and 15 had partial remission, for an objective response rate of 60.0%. The median survival time was 14.9 months, and
the 1- and 2-year survival rates were 51.6% and 34.2%, respectively. The study concluded that the major toxicity of this regimen
was pneumonitis. This therapy may be active against unresectable non-small-cell lung cancer and a phase II study is warranted.
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In patients with unresectable stage III non-small-cell lung cancer
(NSCLC), two or more cycles of cisplatin-based chemotherapy, with
or followed by radiation, has been proven to enhance survival (Amer-
ican Society of Clinical Oncology, 1997). Chemotherapy is
appropriate for selected patients who have a good performance
status. In general, chemotherapy is either given ﬁrst followed by
radiation, or is administered concurrently with radiation. Concur-
rent chemoradiotherapy regimens employ chemotherapy agents as
radiosensitisers. Most studies that have shown a beneﬁt for chemor-
adiotherapy have used cisplatin- or carboplatin-based combinations
(Dillman et al, 1990; Le Chevalier et al, 1991; Jeremic et al, 1995), and
both drugs are known to be radiosensitizers (Schaake-Koning et al,
1992; Jeremic et al, 1996). New active agents, such as paclitaxel, doce-
taxel, gemcitabine, vinorelbine and irinotecan, have been introduced
and clinical trials of these agents for NSCLC have yielded promising
data. These agents have been compared with each other in a phase III
study performed in patients with advanced NSCLC, and several
studies have suggested the radiosensitising properties of these new
agents (Tishler et al, 1992; Leonard et al, 1996; McGinn et al, 1996;
Okishio et al, 1996). However, the phase I and II studies combining
these agents with radiotherapy have mostly been preliminary (Choy
et al, 1994; Greco et al, 1996; Gregor, 1997; Mauers et al, 1998;
Herscher et al, 1998). Irinotecan has a mechanism of action targeting
the nuclear enzyme topoisomerase I as radiosensitiser in vitro
(Okishio et al, 1996). A response rate of 32% was observed in
untreated patients with advanced NSCLC (Fukuoka et al, 1992) while
a recent phase III study showed that irinotecan in combination with
cisplatin achieved a signiﬁcantly better survival compared with the
combination of cisplatin and vindesine in patients with metastatic
NSCLC (Fukuoka et al, 2000). We have already reported that a phase
I/II study of weekly irinotecan with concurrent radiotherapy showed
acceptable toxicity (esophagitis, diarrhea, and pneumonitis)(Takeda
et al, 1999). Carboplatin has also been investigated as a radiosensiti-
zer. Several studies (Groen et al, 1995; Kunitoh et al, 1997; Atagi et al,
2000) of concurrent daily carboplatin and radiotherapy have
suggested that this combination is feasible and reasonably effective.
Irinotecan and carboplatin have independently shown a synergistic
effect with ionizing radiation in preclinical studies (Douple et al,
1985; Okishio et al, 1996). Based on these ﬁndings, we conducted a
phase I trial of daily carboplatin and weekly irinotecan with concur-
rent thoracic radiotherapy for the treatment of locally advanced
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mate the antitumor activity and toxicity proﬁle of this therapy.
MATERIALS AND METHODS
Patients selection
Patients were eligible for this study if they had histologically or cyto-
logically documented and locally advanced stage III NSCLC that was
deemed unresectable. Other eligibility requirements included an age
of less than 75 years, an Eastern Cooperative Oncology Group
performance status (PS) of 0 to 2, no previous chemotherapy or
radiotherapy, ability to give written informed consent, as well as
adequate pretreatment haematologic function (leukocyte count
54000 ml
71, haemoglobin 59.5 g dl
71, and platelet count
5100000 ml
71), renal function (a normal serum creatinine concen-
tration), hepatic function (transaminases 4twice the normal range
and serum bilirubin level 41.5 mg dl
71), and pulmonary function
(PaO2 570 Torr, %DLco 460%). Patients were excluded if they
had contralateral hilar lymph node metastasis, a serious pre-existing
disease, or a radiation ﬁeld that exceeded half of one lung. Patient’s
informed consent and approval of the institutional ethics committee
were mandatory for participation in the trial.
Treatment plan
Irinotecan was administered as a 90-min intravenous infusion once
weekly, and carboplatin was given as a 30-min infusion
(20 mg m
72) prior to thoracic radiotherapy daily for 5 days each
week. Irinotecan and carboplatin were both administered for 4 weeks.
Thoracic radiotherapy started on day 1 and was given to a total
dose of 60 Gy in 2.0 Gy fractions, which were delivered ﬁve times
a week for 6 weeks using a linear accelerator (54MV). The treat-
ment volumes consisted of original and boost volumes irradiated
sequentially. The initial large-ﬁeld target volume consisted of the
primary tumour, mediastinum, and involved hilar of supraclavicular
nodes (total dose, 40 Gy), and boost dose of 20 Gy was delivered to
a volume that consisted of the primary tumour and involved nodes.
A combination of parallel-opposed anterior and posterior and obli-
que ﬁelds was used. The maximal spinal cord dose did not exceed
40 Gy. The target volume of the primary tumour included the
complete extent of the visible primary tumour as deﬁned radiogra-
phically (by computed tomography) with a minimum 1.5 cm and a
maximum 2.5 cm margin around the mass.
The following therapy is optional. If the patient became operable
as a result of tumour regression, surgery was done within 1 month
of the completion of chemoradiotherapy. If the patient remained
inoperable, two cycles of cisplatin with vindesine (cisplatin
80 mg m
72 day 1 and vindesine 3 mg m
72 on days 1, 8, 15) were
given as systemic chemotherapy.
Dose escalation schedule
The starting dose of irinotecan was 30 mg m
72 and this was esca-
lated by 10 mg m
72 increments in every three patients. There was
no interpatient escalation. The next scheduled dose of irinotecan
was omitted when grade 3 leukopenia, thrombocytopenia, or grade
2 diarrhea was observed.
Boththoracicradiotherapyandintravenouscarboplatinwerewith-
held if grade 3 leukopenia, neutropenia, thrombocytopenia, or grade
4 esophagitis was observed and restarted as soon as possible after
recovery to grade 3 esophagitis and grade 2 haematological toxicity.
Dose-limiting toxicity
Dose-limiting toxicity was deﬁned as grade 3 or 4 nonhaematologic
toxicity, excluding nausea, vomiting, and alopecia, as neutropenic
fever (grade 3 neutropenia and 4388C) or as grade 4 haematologic
toxicity according to the WHO criteria (World Health Organization,
1979). If irinotecan was omitted two times or more due to any toxi-
city or radiotherapy and daily carboplatin was postponed for more
than one week because of grade 3 haematological toxicity or grade
4 oesophagitis, we decided this was dose-limiting toxicity. If dose-
limiting toxicity was observed in one or two out of three patients,
an additional three patients were scheduled to be treated at the same
dose level, and dose escalation could then continue if the toxicity was
only observed in one or two out of six patients. If the dose-limiting
toxicity was observed in all three patients or in more than three out
of six patients, that dose was deﬁned as the maximum tolerated dose.
Recommended dose was deﬁned the previous dose level.
Response and toxicity evaluation
Responses were evaluated according to the World Health Organiza-
tion (WHO) criteria and toxicity was assessed prior to any further
non-protocol therapy according to the WHO criteria (World
Health Organization, 1979). Pulmonary toxicity was recorded as
Grade 0–5 according to late Radiation Therapy Oncology Group
(RTOG) criteria (Robert et al, 1999) as follows: 0, none; 1, asymp-
tomatic or mild symptoms, slight radiographic appearances; 2,
moderate symptomatic ﬁbrosis or pneumonitis, low-grade fever,
patchy radiographic appearances; 3, severe symptomatic ﬁbrosis
or pneumonitis, dense radiographic changes; 4, severe respiratory
insufﬁciency, continuous oxygen, assisted ventilation; and 5, fatal.
All reported responses and toxicities were conﬁrmed by indepen-
dent extramural review. Survival was measured from the initiation
of chemoradiotherapy to death, and survival curves were estimated
using the Kaplan–Meier method (Kaplan and Meier, 1958).
RESULTS
Patient characteristics
Between May 1996 and July 1998, 31 patients with histologically or
cytologically conﬁrmed stage III NSCLC were enrolled in this dose
escalation study. Their clinical characteristics are summarised in
Table 1. Four dose levels of irinotecan were administered (Table
2), and 30 patients were assessable for toxicity and efﬁcacy. The
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Table 1 Patient characteristics
No. of patients enrolled 31
Evaluability
Not evaluable 1
a
Response and toxicity 30
Age; median (range) years 62 (52–72)
Performance status (ECOG)
0 10 (33%)
1 18 (60%)
2 2 (7%)
Sex
Male 24 (80%)
Female 6 (20%)
Histology
Squamous cell carcinoma 19 (63%)
Adenocarcinoma 10 (33%)
Large cell carcinoma 1 (3%)
Stage
IIIA 12 (40%)
IIIB 18 (60%)
Abbreviation: ECOG, Eastern Cooperative Oncology Group.
aA brain metastasis was
discovered on day 7 of treatment, and this patient was removed from the study.
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50 mg m
72 was ineligible because brain metastasis was conﬁrmed
after enrollment. For these 30 patients, the median age was 62 years
(range: 52–72 years). The performance status was 0–1 in 28
patients, while it was 2 in two patients. Twelve patients were in
stage IIIA and 18 were in stage IIIB. Their tumours included 19
squamous cell carcinomas, 10 adenocarcinomas, and one large cell
carcinoma.
Actual doses of chemotherapy and radiotherapy
The planned individual drug doses, the actual delivered doses and
dose intensity are listed in Table 2. Fourteen patients were treated
with 30 mg m
72 of irinotecan. Although six patients should have
been the maximum number in one step in our protocol, we added
eight patients in ﬁrst step to carry out this protocol safely because
grade 4 pulmonary toxicity was observed in one patient, in the
former study (Takeda et al, 1999) of weekly irinotecan combined
with concurrent thoracic radiation therapy we experienced the
treatment related death of pneumonitis and the Monitoring
Committee of this protocol decided to add more patients in initial
step. Administration of irinotecan was withheld due to neutropenia
in three patients, disease progression in two patients, and diarrhea
and localized erythema in one patient. Three patients did not
complete the intravenous carboplatin schedule, one due to disease
progression and the other due to a mistake about administration
times. Dose intensities of irinotecan and carboplatin are listed in
Table 2. The percentage of actually delivered dose-intensity of
irinotecan and carboplatine was range from 91.1% to 100%.
Twenty-ﬁve out of the 30 patients (83.3%) completed their radio-
therapy as scheduled. The reason for not completing radiotherapy
was disease progression in two patients and thrombocytopenia in
one patient. Also, the ﬁrst patient who received 60 mg m
72 of
irinotecan suffered treatment-related death from pneumonitis and
thrombocytopenia, so the other two patients treated at this dose
level discontinued radiotherapy after 50 Gy.
Haematologic toxicity
Thirty patients were assessable for haematologic toxicity, and the
results summarised in Table 3. Haematologic toxicities were mild.
The only grade 4 leukopenia and neutropenia were seen in one
patient (grade 4 neutropenia) given 30 mg m
72 of irinotecan. G-
CSF was administered to ﬁve of 14 patients on 30 mg m
72 of
irinotecan, three of six on 40 mg m
72, four of seven on
50 mg m
72, and all three on 60 mg m
72 dose of irinotecan. Grade
4 thrombocytopenia occurred in two patients (one at the
50 mg m
72 and one at 60 mg m
72 doses of irinotecan) and this
was dose-limiting toxicity. These two patients required platelet
transfusions.
Nonhaematologic toxicity
The nonhaematologic toxicities are summarised in Table 4. One
patient suffered from grade 3 esophagitis at an irinotecan dose of
40 mg m
72, and two patients had grade 3 nausea with vomiting
at 30 mg m
72 of irinotecan. No patient suffered from either grade
3 or 4 diarrhea. Grade 4 pneumonitis was observed in two patients
treated with 60 mg m
72 of irinotecan, as well as in one patient
each at both 30 mg m
72 and 40 mg m
72. Grade 5 pneumonitis
was observed in one patient with 60 mg m
72 of irinotecan. Grade
4–5 pneumonitis was dose-limiting toxicity and was observed in
all three patients at the 60 mg m
72 of irinotecan dose. Therefore
we decided that this dose was deﬁned as the maximum tolerated
dose. Of these ﬁve patients who had grade 4–5 pneumonitis, all
were treated with steroids and three required mechanical ventila-
tion. Four patients eventually recovered, however one patient
given 60 mg m
72 of irinotecan suffered treatment-related death.
Pneumonitis seemed to be a principal toxicity of this combined
modality.
Response
The response to treatment is summarised in Table 5. Three patients
achieved complete remission and 15 patients achieved partial
remission, for an overall objective response rate of 60.0% (95%
conﬁdence interval 41.4–78.6%). Among the 18 responders, ﬁve
patients underwent surgical resection of their residual disease and
ﬁve received systemic chemotherapy with cisplatin and vindesine.
Among the 11 patients with stable disease, four also received
systemic chemotherapy.
Survival and duration of response
The overall median survival time (MST) was 14.9 months, while the
1-year and 2-year survival rates were 51.6% and 34.2%, respectively.
In the responding patients (i.e., those who achieved either complete
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Table 2 Dose levels of irinotecan, dose actually delivered and dose intensity
Irinotecan No. of
(mg m
72) evaluable Administration DI (mg m
72 per week) Administration DI (mg m
72 per day) Treatment of
dose level patients of irinotecan (% of ADDI) of carboplatin (% of ADDI) radiotherapy
30 14 complete 10 27.3 complete 13 19.0 complete 12
one dose missed 3
a,b,c (91.1%) 6 doses 1
b (95.0%) 28 Gy 1
b
two doses missed 1
b 12 Gy 1
b
40 6 complete 5 38.3 complete 5 19.8 complete 6
one dose missed 1
d (95.8%) 19 doses 1
e (99.2%)
50 7 complete 6 48.2 complete 6 19.9 complete 6
one dose missed 1
a (96.4%) 19 doses 1
e (99.3%) 52 Gy 1
a
60 3 complete 2 55 complete 3 20.0 complete 1
one dose missed 1
a (91.7%) (100%) 50 Gy 2
Abbreviation: DI, dose-intensity, ADDI, actually delivered dose intensity.
aMyelosuppression,
bdisease progression,
cskin rash,
ddiarrhoea,
emistake.
Table 3 Haematologic toxicity
Toxicity (WHO grade)
Irinotecan
dose level No. of
Haemoglobin Neutrophils Platelets
(mg m
72) patients 3 4 3 4 3 4
30 14 1 0 2 1 1 0
40 6 1 0 2 0 0 0
50 7 0 0 2 0 0 1
60 3 0 0 3 0 0 1
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British Journal of Cancer (2002) 87(3), 258–263 ã 2002 Cancer Research UKor partial remission), the median duration of response was 11.0
months. In the patients who had either surgery or adjuvant
chemotherapy, the MST was 21.9 months (range: 7.8 to 33.0 months)
and 24.3 months (range: 5.4 to 32.4 months), respectively. In the
other patients, the MST was 10.6 months (range: 1.1 to 36.9 months).
The overall survival of all the patients is plotted in Figure 1.
Pattern of failure
The sites of initial relapse are shown in Table 6. There were 22 sites
of relapse in 29 patients who had partial remission or stable
disease. The primary tumour inside the radiation ﬁeld was the site
of initial relapse in eight patients (seven without and one with
distant metastasis), while distant metastasis was in ten patients
and pleural effusion in four patients. Of ﬁve patients who under-
went surgery, three patients had no relapse, one died of another
disease, and one had pulmonary metastasis.
DISCUSSION
Our present study showed that the combination of daily low-dose
carboplatin and weekly irinotecan with concurrent thoracic radio-
therapy is feasible. All three patients who received 60 mg m
72 of
irinotecan developed grade 4–5 pneumonitis, although grade 4–
5 pneumonitis was not observed at the 50 mg m
72 dose. In our
former study of a phase I/II study (Takeda et al, 1999) of weekly
irinotecan alone and concurrent thoracic radiotherapy in patients
with stage III NSCLC, radiation therapy (2 Gy daily to a total dose
of 60 Gy) was performed concurrently with administration of
irinotecan done once weekly for 6 weeks. Twenty-seven patients
were enrolled at three irinotecan dose levels (30, 45 and
60 mg m
72). In that phase I study, grade 4 pneumonitis occurred
in one patient at a dose of 60 mg m
72, while in the phase II study
using 45 mg m
72, one out of 10 patients developed severe toxicity
(grade 4 pneumonitis plus grade 3 diarrhea) and died. In our
study, the irinotecan administration period was reduced from 6
to 4 weeks because in our former study (Takeda et al, 1999) the
number of patients increased who experienced the skip of the
5th and/or 6th administration of irinotecan. On the former study
we added the daily carboplatin as another radiosensitiser.
Development of pulmonary toxicity is generally thought to be
related to radiation dose, method of fractionation, and volume
of the lung irradiated (Ginsberg et al, 1993). In patients receiving
combined chemoradiotherapy, other confounding factors, such as
the type of chemotherapeutic agent, also may play an important
role in determining the risk of this toxicity. New chemotherapeutic
agents, such as paclitaxel, have also been reported to show pulmon-
ary toxicity (Choy et al, 1998). Therefore, the mechanism of
pneumonitis seemed to be an interaction between all three parts
of the treatment.
C
l
i
n
i
c
a
l
Table 4 Nonhaematologic toxicity
Toxicity (WHO grade) (RTOG grade)
Irinotecan
dose level No. of
Esophagitis Diarrhoea
Nausea/
Vomiting Pneumonitis
(mg m
72) patients 3 4 3 434345
3 0 1 4 000020210
4 0 6 100000010
5 0 7 000000000
6 0 3 000000021
Table 5 Response to treatment
Irinotecan
dose level No. of
Response
Response
(mg m
72) patients CR PR SD PD rate (%)
30 14 1 5 7 1 42.8
40 6 0 6 0 0 100.0
50 7 1 3 3 0 57.1
60 3 1 1 1 0 66.7
Overall 30 3 15 11 1 60.0
(41.4–78.6)
a
CR=complete remission; PR=partial remission; SD=stable disease; PD=progressive
disease;
a95% conﬁdence interval.
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Figure 1 Overall survival. The estimated 1- and 2-year survival rate were
51.6 and 34.2%, and the median survival time was 14.9 months.
Table 6 Initial relapse sites
Initial relapse site Patients (n)%
Inside radiation ﬁeld 8 27
Primary tumour site 7
b 23
Mediastinal lymph node 1 3
Outside radiation ﬁeld 14 47
Pleural effusion 4 13
Bone 3 10
Lung 2
b 7
Supraclavicular lymph node 1 7
Liver 1 3
Skin 1 3
Spinal cord 1 3
Response continued 5 17
Unknown
a 31 0
aPatients died without disease progression, including one who had treatment-related
death, two who died of other diseases.
bOne patient had two (primary, lung)
simultaneous initial relapse sites.
Irinotecan, carboplatin, and TRT in NSCLC
M Yamada et al
261
ã 2002 Cancer Research UK British Journal of Cancer (2002) 87(3), 258–263Recent studies suggest that analysis of the three-dimensional
dose distribution gives useful data for the prediction of pulmon-
ary toxicity (Martel et al, 1994; Marks et al, 1997; Graham,
1997). We could not calculate radiotherapy volume data since
three-dimensional (3D) radiation therapy were not available with
our study. So we calculated radiation portal size by two-dimen-
sional treatment planning data. Radiation portal size was range
from 105 m
2 to 322 m
2 (mean+SD; 179.7+48.0 m
2). For ﬁve
patients with grade 4 or 5 pulmonary toxicity, radiation ﬁeld
size was range from 168 m
2 to 304 m
2 (mean+SD;
208.8+54.4 m
2). There was no signiﬁcant relationship between
radiation ﬁeld size and pulmonary toxicity. It is very difﬁcult
to interpret the toxicity without more information about radia-
tion volume data. This study thinks it is also worth reporting
the premorbid lung function data, so we collected the individual
data of pulmonary function tests (PFTs) before radiotherapy.
Premorbid lung function data (including spirometry, volume
measurements, and diffusion capacity) as follows (mean+SD):
the per cent predicted vital capacity (%VC) 89.4+19.2%; the
forced expiratory volume in 1 sec (FEV1) 1.88+0.58 L; the
per cent predicted diffusion capacity to carbon monoxide
(%DLCO) 90.1+21.7%. For ﬁve patients with grade 4 or 5
pulmonary toxicity, lung function data as follows (mean+SD):
%VC 93.6+15.9%; FEV1.0 1.91+0.67L; %DLCO 78.0+23.5%.
There was no relationship between PFT parameters and pulmon-
ary toxicities. According these limited information, we suggest
that pulmonary toxicity may be drug related rather than ﬁeld
size or baseline PFTs. In our study, radiation volume was not
estimated, so we have to plan further study to reveal whether
a dose and radiation volume are related to the occurrence of
pulmonary toxicity.
The efﬁcacy of combined-modality therapy for inoperable stage III
NSCLC is reported to vary and the reason for this is unclear, although
differences between the eligibility criteria used in various studies may
account for the different outcomes (Mattson et al, 1988; Morton et al,
1991; Sause et al, 1995). In the present study, the maximum tolerated
dose of irinotecan was 60 mg m
72. Pneumonitis, esophagitis,
thrombocytopenia and neutropenia were the dose-limiting toxicities
and pneumonitis was the principal toxicity of this regimen, whereas
myelosuppression was mild. The overall response rate was 60.0%,
while in patients given 50 and 40 mg m
72 of irinotecan, the response
rate was 57.1 and 100%, respectively. At an irinotecan dose of 40 or
50 mg m
72, pneumonitis was manageable and haematologic toxicity
was mild. Based on our ﬁndings we therefore decided that
50 mg m
72 of irinotecan was the recommended dose. Although
these data are still preliminary, the median survival time was 14.9
months and the 1- and 2-year survival rates were 51.6 and 34.2%,
respectively, which were reasonably good. When comparing these
results with similar combined modality studies, the MST and survival
rates are most encouraging. And the MST of 21.9 months and 24.3
months in patients who underwent surgery or had adjuvant
chemotherapy was better than that in patients who had no additional
treatment. It is because that optional treatment was done in respond-
ing patients or stable patients. It should be discussed whether in
responding patients additional treatment is necessary.
In conclusion, irinotecan combined with daily carboplatin for 4
weeks and concurrent thoracic radiotherapy appears to be feasible
and improve the survival of patients with unresectable locally
advanced NSCLC. MTD and recommended dose of irinotecan were
60 mg m
72 and 50 mg m
72, respectively. Principal toxicity of this
combined modality was pneumonitis. A phase II study of this
combination is warranted.
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